Bulk Deal: 2 Stocks in Focus After Investors Bought Stakes in the Companies

Synopsis: Key institutional and private investors made notable stake purchases in two companies, signaling confidence in their outlook while slightly reshaping shareholding patterns through secondary market transactions. 

Bulk deals are large-volume transactions in listed equities where a significant number of shares are traded in a single window, typically by institutional investors. These deals often indicate strategic stake changes, reflecting entry, exit, or portfolio rebalancing. While they can influence short-term market sentiment and liquidity, bulk deals do not always signal fundamental shifts, but they are closely tracked for cues on investor confidence and sectoral trends. 

SG Finserv

SG Finserv is a non-banking financial company (NBFC) engaged in providing financial services such as lending, investment activities, and structured financing solutions. The company focuses on capital market-linked opportunities and aims to grow through strategic investments, prudent risk management, and expanding its financial services portfolio. 

S Gupta Holding Private Limited acquired 3.75 lakh shares of SG Finserv at a price of Rs. 564.14 per share, taking the total transaction value to approximately Rs. 21.15 crore, indicating a focused investment in the company. 

With the market capitalization of Rs. 3,687 Crores, the shares of SG Finserv Ltd were trading at around Rs. 560 per share which is 3.6 percent discount from its 52-week high of Rs. 581 per share and is trading at a P/E of 28.9 whereas industry P/E stands at 18.2 

Revenue from operations has increased on a quarterly basis from Rs. 86 Crores to Rs. 105 Crores, up 22 percent. Operating profit has increased from Rs. 43 Crores to Rs. 56 Crores, up 30 percent and net profit has increased from Rs. 32 Crores to Rs. 42 Crores, up 31.25 percent 

Emcure Pharmaceuticals

Emcure Pharmaceuticals is an India-based pharmaceutical company engaged in developing, manufacturing, and marketing a wide range of medicines. It has a strong presence in domestic and international markets, focusing on therapeutic areas like oncology, cardiology, and anti-infectives, supported by research and manufacturing capabilities. 

Norges Bank, on behalf of the Government Pension Fund Global, purchased 18 lakh shares (0.9percent  stake) in Emcure Pharmaceuticals for Rs. 289.47 crore at Rs. 1,608.2 per share from BC Investments IV, which earlier held a 3.87percent  stake as of March 2026. 

With the market capitalization of Rs. 31,559 Crores, the shares of Emcure Pharmaceuticals Ltd were trading at around Rs. 1665 per share which is 5.9 percent discount from its 52 weeks high of Rs. 1770 per share and is trading at a P/E of 34.9 whereas industry P/E stands at 29.8 

Revenue from operations has increased on a quarterly basis from Rs. 2270 Crores to Rs. 2363 Crores, up 4 percent. Operating profit has increased from Rs. 475 Crores to Rs. 493 Crores, up 3.7 percent and net profit has decreased from Rs. 251 Crores to Rs. 231 Crores, down 8 percent 

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Bulk Deal: 2 Stocks in Focus After Investors Bought Stakes in the Companies appeared first on Trade Brains.